Shattuck Labs, Inc.

Phase II data for ALX Oncology’s evorpacept in gastric cancer raises the possibility that the company can succeed in an immunotherapy field that even some large drug companies have exited due to resul

Shattuck Labs, Inc. is moving to focus its clinical efforts on autoimmune diseases with SL-325 after deciding to discontinue its hematology-oncology candidate, SL-172154, due to efficacy that did not

The market for initial public offerings in the US heated up in September with five biopharmaceutical companies launching IPOs, the second busiest month for first-time offerings in 2024 after there wer

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Ono, Numab Partner On Macrophage P